MD ANDERSON CANCER CENTER signed a three-year translational and clinical research agreement with MedImmune to develop anti-cancer immunotherapies through the center’s Moon Shots Program. MedImmune is the global biologics research and development arm of AstraZeneca.
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
